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After a median follow-up of
81 months, the overall sur-
vival of 19,565 radiation-
treated high-risk prostate
cancer patients was posi-
tively associated with the
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comes has been well-documented in surgery, there is little data about whether this ef-
fect exists for radiation-treated patients. We investigated whether treatment at a
radiation facility that treats a high volume of prostate cancer patients is associated with
improved survival for men with high-risk prostate cancer.
Methods and Materials: We used the National Cancer Database (NCDB) to identity
patients diagnosed with prostate cancer from 2004 to 2006. The radiation case volume
(RCV) of each hospital was based on its number of radiation-treated prostate cancer
patients. We used propensity-score based analysis to compare the overall survival
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adjustment for baseline
characteristics (adjusted
hazard ratio: 0.97; 95%
confidence interval: 0.95-
0.98; P<.0001), suggesting
that, similar to the volume
effect in surgically treated
patients, higher radiation
case volume of the treating
facility is associated with
improved outcomes.sociodemographic factors, radiation type, and use of androgen deprivation therapy
(ADT).
Results: A total of 19,565 radiation-treated high-risk patients were identified. Median
follow-up was 81.0 months (range: 1-108 months). When RCV was coded as a contin-
uous variable, each increment of 100 radiation-managed patients was associated with
improved OS (adjusted hazard ratio [AHR]: 0.97; 95% confidence interval [CI]: 0.95-
0.98; P<.0001) after adjusting for known confounders. For illustrative purposes, when
RCV was dichotomized at the 80th percentile (43 patients/year), high RCV was asso-
ciated with improved OS (7-year overall survival 76% vs 74%, log-rank test PZ.0005;
AHR: 0.91, 95% CI: 0.86-0.96, PZ.0005). This association remained significant when
RCV was dichotomized at 75th (37 patients/year), 90th (60 patients/year), and 95th
(84 patients/year) percentiles but not the 50th (19 patients/year).
Conclusions: Our results suggest that treatment at centers with higher prostate cancer
radiation case volume is associated with improved OS for radiation-treated men with
high-risk prostate cancer.  2016 The Authors. Published by Elsevier Inc. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction
Numerous studies have reported that hospital volume as
well as surgeon volume are independent predictors of long-
term outcomes in surgically treated cancer patients (1-5).
This association was attributed to the hospital and sur-
geon’s experience which yielded improved rates of
achieving negative margins (6-8) and higher rates of dis-
secting involved lymph nodes (6, 9, 10). However, there is
limited data about whether this volume effect exists in
radiation-treated cancer patients (11), and whether treat-
ment at a radiation facility that treats a high case volume of
cancer patients is associated with improved survival (12).
To explore this possibility, we conducted a nationwide
cancer database analysis to specifically compare the overall
survival of radiation-treated high-risk prostate cancer in
high versus low radiation case volume (RCV) facilities.
Methods and Materials
Data source and study population
Our study population was derived from the National Cancer
Database (NCDB), a joint program of the Commission on
Cancer (CoC) and the American Cancer Society (ACS).
NCDB is a nationwide hospital-based database capturing
70% of newly diagnosed cases and those cases are diagnosed
and treated at CoC accredited cancer programs (13). Patients
diagnosed with non-metastatic prostate adenocarcinoma
(site code: C61.9, International Classification of Disease for
Oncology code, 3rd edition: 8140) and treated only with
external beam radiation therapy (EBRT) and/or brachyther-
apy in 2004 to 2006 were identified (NZ114,530). In our
analysis, we excluded patients with unknown tumor stage
(nZ2889), Gleason score (nZ4238) or prostate-specific
antigen (PSA) (nZ5562) level to ensure precisely definedNational ComprehensiveCancer Network (NCCN) high-risk
patients. Patients whose radiation therapy was delivered at
multiple places or whose facility information was unknown
were further excluded (nZ9304). In the final study popula-
tion, there were 92,537 patients and 1099 facilities. Patients
were followed until 2012. The institutional review board
approved this study. Figure 1 summarizes the study popula-
tion selection process.Primary endpoint and covariates
The primary endpoint is the effect of RCV on overall sur-
vival. To determine the RCVof each facility, the cumulative
radiation-treated prostate cancer patients from all risk
groups at each facility during 2004-2006 was calculated.
We first analyzed RCV as a continuous variable. Then for
illustrative purposes, we dichotomized RCV into high
versus low RCV at the 80th percentile of numbers of pa-
tients treated per facility. We chose the 80th percentile as
the cutoff because the top 20% of facilities treated 54% of
all the prostate cancer cases and 50% of the high-risk dis-
ease, meaning that about half of patients were treated at
high-volume versus low-volume facilities under this defi-
nition. We also performed sensitivity analyses using various
cutoffs for percentiles of RCV (50th, 75th, 90th, or 95th).
After the RCVof each facility was defined, we investigated
the association between RCV and overall survival specif-
ically in high-risk prostate cancer (NZ19,565). We chose
to study exclusively high-risk prostate cancer because these
are the patients who are most likely to die from prostate
cancer and in whom we would be most likely to observe a
difference in survival over the follow-up time of 81 months.
Other covariates included in the analysis were socio-
demographic variables such as age (coded as a continuous
variable), race and insurance status, household income,
residence type, percentage of education levels less than high
Non-metastatic prostate adenocarcinoma treated with
RT in NCDB 2004-2006 (N=114,530)
Exclusion Criteria
Missing tumor stage(n=2,889)
Missing Gleason score (n=4,238)
Missing prostate-specific antigen(n=5,562)
Patients treated at multiple places
or unknown facility information (n=9,304)
Patients treated only at the reporting facility (N=92,537)
Summed up the total number of RT-treated patients at
each facility and ranked the 1,099 facilities.
Radiation volume was first modeled as a continuous
variable.For illustrative purposes, radiation volume was
then dichotomized into high vs low radiation volume at
80th percentile of patient number.
High volume facility
(Patient number≥129)
Low volume facility
(Patient number < 129)
Selected high-risk RT-treated patients in 2004-2006
(N=19,565) and followed until 2012.
Compared the survival outcome in High-risk prostate cancer
between high-volume and low-volume facility.
Fig. 1. Flow chart for patient selection. Abbreviations: NCDB Z National Cancer Database; RT Z radiation therapy.
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included Charlson-Deyo comorbidity score (0, 1,2), tumor
stage (AJCC 6th Cancer Staging Manual, American Joint
Committee onCancer, 2002), prostate-specific antigen (PSA,
coded as a continuous variable), Gleason score (6, 7, and 8-
10), radiation type (external beam radiation therapy [EBRT]
only, brachytherapy only, EBRT plus brachytherapy), use of
androgen deprivation therapy (ADT), and hospital setting
(academic/research program was defined as academic;
comprehensive community cancer center, community cancer
center and others were defined as a non-academic setting).
Income and education data were based on 2000 US Census
data (14, 15), and residence type was determined using the
2003 US Department of Agriculture Economic Research
Service (16), and all data were provided by NCDB.Statistical analysis
Descriptive statistics were used to present the baseline
characteristics. Categorical variables were assessed with
c2 test; continuous variables were compared with Studentt test or Mann-Whiney U test as appropriate. We first
modeled RCV as a continuous variable and used Cox-
regression analysis to determine the association between
RCV and overall survival. For illustrative purposes, RCV
was dichotomized at the 80th percentile into high RCV
versus low RCV. We presented the effect of RCVon overall
survival using Kaplan-Meier curves before and after pro-
pensity score-based adjustment using inverse propensity
score weighting (IPSW). The inverse-propensity score
weight was first calculated as 1/(propensity score) for pa-
tients treated at high-volume facility and 1/(1-propensity
score) for patients treated at low-volume facility and then
further stabilized the weight with a constant as described by
Robins et al (17). Propensity score was generated on a
multivariate logistic regression model to estimate the
probability of being treated in a high- or low-RCV facility.
The covariates included in the propensity model were all
the patient baseline characteristics as provided in Table 1.
We compared the results from the IPSW-adjusted model
to multivariate Cox proportional hazard models. All sta-
tistical analyses were performed using SAS version 9.4
software (SAS Institute Inc, Cary, NC) and figures were
Table 1 Patient baseline characteristics
Characteristic High volume Low volume
P value
Unadjusted
IPTW
adjusted
Total patient number (%) 9817 (50.2) 9748 (49.8)
Median patient number (IQR) 223 (161-348) 76 (47-103)
Mean age (95% CI) 69.2 (69.0-69.3) 69.7 (69.5-69.9) <.0001 .88
Race (%) <.0001 .97
Non-Hispanic whites 7303 (74.4) 7469 (76.6)
African American 1595 (16.3) 1533 (15.7)
Hispanic whites 356 (3.6) 378 (3.9)
Others 387 (3.9) 262 (2.7)
Unknown 176 (1.8) 106 (1.1)
Insurance status <.0001 .99
None 112 (1.1) 158 (1.6)
Private 3453 (35.2) 2632 (27)
Medicaid 184 (1.9) 265 (2.7)
Medicare 5751 (58.6) 6252 (64.1)
Others 160 (1.6) 238 (2.4)
Unknown 157 (1.6) 203 (2.1)
Charlson comorbidity index
0 8892 (90.6) 8750 (89.8) .105 .98
1 803 (8.2) 852 (8.7)
2þ 122 (1.2) 146 (1.5)
Median PSA (IQR) 14.5 (27.7) 20.0 (34.0) <.0001 .90
T stages <.0001 .99
T1 4511 (46.0) 4311 (44.2)
T2 3654 (37.2) 3933 (40.4)
T3 1568 (16.0) 1424 (14.6)
T4 84 (0.9) 80 (0.8)
Gleason score <.0001 .66
6 1651 (16.8) 1906 (19.6)
7 2072 (21.1) 2206 (22.6)
8-10 6094 (62.1) 5636 (57.8)
RT type <.0001 .82
EBRT 6784 (69.1) 7520 (77.1)
Brachytherapy 1355 (13.8) 1432 (14.7)
EBRT plus brachytherapy 1678 (17.1) 796 (8.2)
ADT use .58 .89
Yes 7307 (74.4) 7222 (74.1)
No 2510 (25.6) 2526 (25.9)
Hospital setting <.0001 .75
Academic/research program 3749 (38.2) 2074 (21.3)
Comprehensive community cancer program 5892 (60.0) 5684 (58.3)
Community cancer program 176 (1.8) 1983 (20.3)
Other types 0 (0) 7 (0.1)
Household income <.0001 .99
<$30,000 1124 (11.5) 1468 (15.1)
$30,000-34,999 1466 (14.9) 1976 (20.3)
$35,000-45,999 2498 (25.5) 2702 (27.7)
$46,000 4352 (44.3) 3233 (33.2)
Unknown 377 (3.8) 369 (3.8)
Education level <.0001 .97
29% 1478 (15.1) 1718 (17.6)
20%-28.9% 2008 (20.5) 2350 (24.1)
14-19.9% 2235 (22.8) 2345 (24.1)
<14% 3719 (37.9) 2965 (30.4)
Unknown 377 (3.8) 370 (3.8)
(continued on next page)
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Table 1 (continued )
Characteristic High volume Low volume
P value
Unadjusted
IPTW
adjusted
Residence <.0001 .81
Metropolitan 8240 (83.9) 7081 (72.6)
Urban 1084 (11.0) 2053 (21.1)
Rural 147 (1.5) 289 (3.0)
Unknown 346 (3.5) 325 (3.3)
Abbreviations: ADTZ androgen deprivation therapy; EBRTZ external beam radiation therapy; IPSWZ inverse propensity score weighting; IQRZ
interquartile range; PSA Z prostate-specific antigen; RT Z radiation therapy.
Percentage may not add up to 100 due to rounding. Education level is the percentage of residents with education level < high school within the same
ZIP code of the patient’s residence. Education level and household income were derived from 2000 US Census data. Residence was derived from 2003 US
Department of Agriculture Economic Research Service. Household income, education level, and residence type were determined at the county level.
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College Station, TX). We used a two-sided P value of <.05
in all analyses as criteria for statistical significance.
Results
Baseline characteristics stratified by high versus
low radiation case volume facilities
There were 19,565 radiation-treated high-risk prostate can-
cer patients in the study population. 9817 (50.2%) were
treated at high RCV facilities and 9748 (49.8%) were treated
at low RCV facilities based on the 80th percentile dichoto-
mization. The median number of radiation-treated high-risk
prostate cancer patients was 223 (interquartile range:
161-348) in high RCV facility and 76 (interquartile range:
47-103) in low RCV facility during 2004 to 2006. The me-
dian follow-up time was 81 months (range: 1-108 months).
Patient sociodemographic and clinical characteristics strati-
fied on RCVare summarized in Table 1. Compared with low
RCV facilities, high RCV facilities were more likely to be an
academic setting (38.2% vs 21.3%, respectively) and more
likely to be in a metropolitan area (83.9% vs 72.6, respec-
tively). They also treated a higher proportion of Gleason
score 8 to 10 patients (62.1 vs 57.8, respectively) and T3
patients (16.0 vs 14.6, respectively) and were more likely to
give combination therapy of EBRT with brachytherapy
(17.1% vs 8.2, respectively), although the median PSA was
lower (14.5 vs 20.0, respectively; all P<.0001). ADT use
(PZ.58) and Charlson comorbidity score (PZ.105) did not
differ by high- versus low-RCV facility. After IPSW adjust-
ment, all baseline characteristics were distributed evenly
without statistical significance (all P>.05) between the high-
and low-RCV facilities.
Association between radiation case volume and
survival
When RCV was analyzed as a continuous variable, each
increment of 100 patients treated was associated withimproved overall survival (adjusted hazard ratio [AHR]:
0.97, 95% confidence interval [CI]: 0.95-0.98, P<.0001)
after adjusting for known confounders (Table 2).
The Kaplan-Meier curves illustrate overall survival
stratified by high and low RCV before and after IPSW
adjustment (Figs. 2 and 3). In unadjusted analysis, the
7-year overall survival was statistically higher in high RCV
facilities (77% vs 73%, respectively; log-rank test
P<.0001) (Fig. 2). This survival benefit was smaller but
persisted after IPSWadjustment (76% vs 74%, respectively,
log-rank test PZ.0005) (Fig. 3).
Table 3 presents overall survival hazard ratios
comparing high with low RCV facilities from the unad-
justed Cox regression, multivariate Cox regression, and
IPSW-adjusted models. On multivariate Cox regression,
high versus low RCV was associated with improved OS
(AHR: 0.91, 95% CI: 0.86-0.97, PZ.002), and this was
confirmed with nearly identical results for IPSW analysis
(AHR: 0.91, 95% CI: 0.86-0.96, PZ.0005). In sensitivity
analysis, in models in which radiation case volume was
dichotomized at other cutoffs, improved overall survival
was observed at the 75th, 90th, and 95th percentiles, cor-
responding to >37, >60, and >84 prostate patients,
respectively, treated at the facility per year. However, at the
50th percentile (>19 patients per year), there were no
survival differences (AHR: 0.99, 95% CI: 0.92-1.07,
PZ.78) (Table 4).Discussion
To our knowledge, our study is one of the first and largest
demonstrating that similar to the hospital and surgeon
volume effect on surgically treated patients (5), the higher
radiation case volume of the treating facility is associated
with improved overall survival in high-risk prostate cancer
patients. We believe this case volume effect is likely true
for other disease sites besides prostate cancer, as Wang et al
(12) also recently reported improved survival for patients
treated at high-volume facilities in the setting of concurrent
chemoradiation for stage III non-small cell lung cancer.
Table 2 Multivariate Cox regression analysis
Variable AHR (95% CI) P value
Increment of 100 patients 0.97 (0.95-0.98) <.0001
Increment of 1-y age 1.05 (1.04-1.05) <.0001
Increment of 1-unit PSA 1.004 (1.003-1.005) <.0001
Race
Black 1.00 (0.91-1.09) .93
Hispanic-white 0.70 (0.59-0.84) <.0001
Other 0.78 (0.65-0.92) .004
Non-Hispanic white Ref NA
Insurance status
Private insurance 0.97 (0.71-1.31) .83
Medicaid 1.41 (0.99-2.00) .05
Medicare 1.04 (0.77-1.40) .82
Other 1.26 (0.87-1.81) .22
Uninsured Ref NA
Charlson comorbidity score
2þ 2.28 (1.90-2.73) <.0001
1 1.50 (1.37-1.64) <.0001
0 Ref NA
Tumor stage
T4 3.06 (2.46-3.79) <.0001
T3 1.41 (1.30-1.54) <.0001
T2 1.10 (1.03-1.17) .0033
T1 Ref NA
Gleason score
8-10 1.77 (1.60-1.95) <.0001
7 1.23 (1.11-1.37) .0001
<Z6 Ref NA
Hospital setting
Academic 0.97 (0.90-1.03) .32
Nonacademic Ref NA
Use of ADT
ADT 0.97 (0.90-1.04) .40
No ADT Ref NA
Radiation type
EBRT plus brachytherapy 0.67 (0.61-0.74) <.0001
Brachytherapy only 0.83 (0.76-0.92) .0002
EBRT only Ref NA
Household income
$46,000 0.81 (0.73-0.91) .0003
$35,000-45,999 0.86 (0.78-0.95) .003
$30,000-34,999 1.00 (0.91-1.09) .92
<$30,000 Ref NA
Education level
<14% 0.82 (0.73-0.92) .001
14%-19.9% 0.87 (0.79-0.96) .005
20-28.9% 0.94 (0.86-1.03) .18
29% Ref NA
Residence
Rural 1.03 (0.86-1.23) .75
Urban 1.01 (0.94-1.10) .74
Metropolitan Ref NA
Abbreviations: ADT Z androgen deprivation therapy; AHR Z
adjusted hazard ratio; EBRT Z external beam radiation therapy;
NA Z not applicable; PSA Z prostate-specific antigen.
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fect. One reason may relate to the quality of the radiation
that can be delivered by a high case volume radiation center.Radiation requires close collaboration between the treating
physicians, dosimetrists, physicists, and therapists to ensure
exactly the right targets are outlined, the optimal plan is
generated, and right targets are hit every day. Judgment on
the part of radiation oncologist is required throughout the
contouring process to decide on which areas should be
treated and which should be left out (18), and expertise
gained from working at a higher case volume facility can
lead to better judgment about which areas are likely to
harbor disease (11). Physicians at higher case volume cen-
ters may also feel more comfortable with using higher
doses, as shown by their increased use of the external beam
plus brachytherapy combination, which delivers much
higher doses to the prostate than external beam radiation
alone and which has been associated with significantly
improved outcomes in a recently reported randomized trial
(19). Interestingly, we observed our effect even after
adjusting for the difference in treatment technique and dose,
Table 3 Overall survival hazard ratios comparing high
versus low case volume facilities
Continuous variable Model AHR (95% CI) P value
Increment of 100 patients 0.97 (0.95-0.98) <.0001
Binary models Crude HR (95% CI) P value
Unadjusted 0.83 (0.79-0.88) <.0001
AHR (95% CI) P value
Multivariate Cox
regression model
0.91 (0.86-0.97) .0021
IPSW-adjusted Cox
regression model
0.91 (0.86-0.96) .0005
Abbreviations: AHR Z adjusted hazard ratio; HR Z hazard ratio.
Models were adjusted for age, race, insurance status, tumor stage,
Gleason score, prostate-specific antigen level, Charlson comorbidity
score, use of androgen deprivation therapy, radiation modalities,
household income, education level, hospital type, and residence type.
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be generally more comfortable with taking on a higher risk
of complications to achieve better results.
Local treatment with radiation has been shown to deliver
a 10% overall survival benefit at 10 years for locally
advanced prostate cancer (20), so it is plausible that the 2%
difference at 7 years that we observed in overall survival is
partly related to radiation quality, but another reason for the
finding could relate to the experience of the providers in
other disciplines at centers that treat high volumes of pros-
tate cancer patients with radiation. The care of cancer pa-
tients is a sophisticated process involving timely diagnosis,
early initiation of guideline-based treatment and post-
treatment follow-up. The care of prostate cancer patients
necessitates multidisciplinary collaboration (21-24) among
urologists, radiation oncologists, medical oncologists, radi-
ologists, and pathologists, and a high case volume facility
has higher likelihood of having experts in all the related
specialties onsite. In such high-volume centers, care is likely
to be well coordinated between specialists and patients are
likely to be treated in a consistent fashion (11, 25-29),
including optimal staging and selection of duration of
androgen deprivation therapy, leading to better outcomes.
The primary implication of our study is that similar to
patients seeking the best surgical outcomes, patients
seeking the best radiation outcomes should also seek out
facilities that treat a high volume of patients with radiation.Table 4 Sensitivity analysis
Binary model percentile for cutoff
(number of RT-treated patients)
% of high-risk pa
in high-volum
95th (>84 vs  84 per year) 20
90th (>60 vs  60 per year) 33
80th (>43 vs  43 per year) 50
75th (>37 vs  37 per year) 58
50th (>19 vs  19 per year) 83
Abbreviation: AHR Z adjusted hazard ratio.As is the case with urologic surgery (5, 30-33) and cardiac
care (34-36), our results suggest that care is best when it is
clustered at high-volume facilities.
Although ours is the largest study and the only one to
focus on high-risk prostate cancer, evidence of a volume
outcome effect could also be gleaned from a secondary
analysis of the Radiation Therapy Oncology Group 0129
trial (11) and a Surveillance, Epidemiology, and End
Results-Medicare study (37) suggesting that among men
with prostate cancer treated with brachytherapy, patients
treated by higher volume physicians had a near-significant
decrease in all-cause mortality (HR: 0.95/100 cases;
PZ.05). Although SEER-Medicare only includes men over
65 years of age and captures only 28% of that population,
our NCDB captures 70% of the population, and so our
study is more generalizable to the greater US population.
By focusing on a high-risk population and having a study
nearly 4 times larger (19,565 vs 5595 patients, respec-
tively), we had ample power to find a very significant as-
sociation between radiation case volume and overall
survival (P<.0001).
Certain limitations of our study should be considered.
First, NCDB is a hospital-based cancer registry and only
cases diagnosed and treated at Commission on Cancer
(CoC) accredited programs were reported. Cases from non-
CoC-accredited programs were unavailable in NCDB.
However, this makes the point that even within CoC-
accredited programs, higher radiation case volume was
associated with better overall survival. Second, our study
design was an observational study, and although
propensity-score based comparative effective analysis was
adopted, we are still subject to unmeasured confounders.
Third, the NCDB only reports the overall survival instead
of cancer-specific survival, so there is a possibility that
patients who were healthier at baseline are the ones who
tend to be treated at higher-volume cancer centers. How-
ever, we attempted to account for this limitation with
adjustment for the Charlson comorbidity score in the
analysis. Fourth, although we adjusted for socioeconomic
status with household income and education level, those
information was the county level data of a patient’s resi-
dence and individual socioeconomic status might not be
fully accounted for. Patients treated at higher RCV facilities
might be of higher socioeconomic status which explained
improved overall survival. Fifth, we didn’t have informa-
tion about the duration of androgen deprivation therapy.tients treated
e facility AHR (95% CI) P value
0.90 (0.84-0.98) .013
0.90 (0.85-0.96) .002
0.91 (0.86-0.97) .001
0.91 (0.86-0.97) .002
0.99 (0.92-1.07) .78
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Despite the potential limitations stated above, our study
may be the first to report a highly significant association
between radiation case volume and improved overall sur-
vival in a radiation-treated patient population. As patients
often do for their surgical care, consideration should be
given to favoring radiation treatment at a center that treats a
high volume of patients with a patient’s particular disease.References
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